Forskning ved Københavns Universitet - Københavns Universitet

Forside

Bicalutamide monotherapy for early stage prostate cancer: an update

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Standard

Bicalutamide monotherapy for early stage prostate cancer: an update. / Iversen, Peter.

I: Journal of Urology, Bind 170, Nr. 6 Pt 2, 01.12.2003, s. S48-52; discussion S52-4.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

Harvard

Iversen, P 2003, 'Bicalutamide monotherapy for early stage prostate cancer: an update', Journal of Urology, bind 170, nr. 6 Pt 2, s. S48-52; discussion S52-4. https://doi.org/10.1097/01.ju.0000096491.61731.38

APA

Iversen, P. (2003). Bicalutamide monotherapy for early stage prostate cancer: an update. Journal of Urology, 170(6 Pt 2), S48-52; discussion S52-4. https://doi.org/10.1097/01.ju.0000096491.61731.38

Vancouver

Iversen P. Bicalutamide monotherapy for early stage prostate cancer: an update. Journal of Urology. 2003 dec 1;170(6 Pt 2):S48-52; discussion S52-4. https://doi.org/10.1097/01.ju.0000096491.61731.38

Author

Iversen, Peter. / Bicalutamide monotherapy for early stage prostate cancer: an update. I: Journal of Urology. 2003 ; Bind 170, Nr. 6 Pt 2. s. S48-52; discussion S52-4.

Bibtex

@article{fd74d16527ab4a10843a060d730361a7,
title = "Bicalutamide monotherapy for early stage prostate cancer: an update",
abstract = "The current evidence is considered to support 150 mg of the nonsteroidal antiandrogen bicalutamide for early stage prostate cancer.",
author = "Peter Iversen",
year = "2003",
month = "12",
day = "1",
doi = "http://dx.doi.org/10.1097/01.ju.0000096491.61731.38",
language = "English",
volume = "170",
pages = "S48--52; discussion S52--4",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier",
number = "6 Pt 2",

}

RIS

TY - JOUR

T1 - Bicalutamide monotherapy for early stage prostate cancer: an update

AU - Iversen, Peter

PY - 2003/12/1

Y1 - 2003/12/1

N2 - The current evidence is considered to support 150 mg of the nonsteroidal antiandrogen bicalutamide for early stage prostate cancer.

AB - The current evidence is considered to support 150 mg of the nonsteroidal antiandrogen bicalutamide for early stage prostate cancer.

U2 - http://dx.doi.org/10.1097/01.ju.0000096491.61731.38

DO - http://dx.doi.org/10.1097/01.ju.0000096491.61731.38

M3 - Journal article

VL - 170

SP - S48-52; discussion S52-4

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6 Pt 2

ER -

ID: 34081104